Tag Archives | genomics

JPMorgan Healthcare Conference Notes #4: Next Gen Sequencing (NGS)

Seminar: Harnessing the Power of Next Gen Sequencing: The View from Industry 1/12/15 A panel of leading entrepreneurial R&D executives presented their outlook and issues on the future of Next Gen Sequencing (NGS), focusing on drug development and future clinical diagnostic applications. The panel was Randy Scott Ph.D. Founder and CEO of Invitae, George Yancopoulos […]

Continue Reading 0

Rayno Life Science: Market Update 11/26… Stocks Cruise To New Highs

NASDAQ leads -up 0.6% to 4787 The October correction of ~7% was a “headfake” as macro events scared many investor away Technology and Healthcare Stocks Lead The Way The healthcare SPDR (XLV) is up 24.5% YTD and the technology SPDR (XLK) is up 18% YTD. Biotech stocks are at new highs with all major ETFs […]

Continue Reading

Rayno Life Science Stocks: Up 30%+ YTD After A Volatile October

Investors Whipsawed By V-Shaped Rally NASDAQ at New Highs 4631 DOW at New Highs 17,390 Investors got what was forecasted-a volatile October that moved from fear to greed in two weeks! The market was buffeted by the Ebola scare, macro analysts decrying easy money from the FED and a potential global economic slowdown. But fears […]

Continue Reading

Market Perks Up on FED Testimony-Rates To Stay Low… Update 1 6/19

Update June 19.. 3:10 p EDT Ten Yr 2.62%, U.S.equities flat,biotech mixed, jobless claims down. Japanese and European equities up. Iraq on front page. GOLD Up $41 Breaks Through Resistance at $1300 Gold futures rose on technicals, Middle East turmoil, a weak dollar and a dovish FED. Silver is also strong.In this week’s Barron’s three […]

Continue Reading

Rayno Dx and Tools 2014 YTD After OCT. Correction: ABAX EXAS ILMN SQNM …Update 12/24/14

Update 11/24/14   Clinical Diagnostics and Tools Stocks Review Performance YTD and compared to 11/13 YTD Top winners YTD are: EXAS 104%, ILMN 71.4%, ABAX 36.8% Top Losers YTD are: NSTG 16.6%, RGDX 54%, VRML 30.9% but all were good trades. IWM at $117.4 See Performance Data Below ———————-Previous post——— April Sell-Off Hit Diagnostic Small […]

Continue Reading